271 related articles for article (PubMed ID: 15023365)
21. Systematic comparison of competitive and allosteric kinase inhibitors reveals common structural characteristics.
Hu H; Laufkötter O; Miljković F; Bajorath J
Eur J Med Chem; 2021 Mar; 214():113206. PubMed ID: 33540355
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of three-dimensional activity cliffs formed by kinase inhibitors with different binding modes and cliff mapping of structural analogues.
Furtmann N; Hu Y; Bajorath J
J Med Chem; 2015 Jan; 58(1):252-64. PubMed ID: 25054653
[TBL] [Abstract][Full Text] [Related]
23. Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome.
Martin E; Mukherjee P
J Chem Inf Model; 2012 Jan; 52(1):156-70. PubMed ID: 22133092
[TBL] [Abstract][Full Text] [Related]
24. Advancing the kinase field: new targets and second generation inhibitors.
Laufer S; Bajorath J
J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
[No Abstract] [Full Text] [Related]
25. The structure-based design of ATP-site directed protein kinase inhibitors.
Toledo LM; Lydon NB; Elbaum D
Curr Med Chem; 1999 Sep; 6(9):775-805. PubMed ID: 10495352
[TBL] [Abstract][Full Text] [Related]
26. A chemogenomics view on protein-ligand spaces.
Strömbergsson H; Kleywegt GJ
BMC Bioinformatics; 2009 Jun; 10 Suppl 6(Suppl 6):S13. PubMed ID: 19534738
[TBL] [Abstract][Full Text] [Related]
27. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases.
Graczyk PP
J Med Chem; 2007 Nov; 50(23):5773-9. PubMed ID: 17948979
[TBL] [Abstract][Full Text] [Related]
28. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening.
Chuaqui C; Deng Z; Singh J
J Med Chem; 2005 Jan; 48(1):121-33. PubMed ID: 15634006
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-dependent kinase inhibitors.
Fischer PM; Endicott J; Meijer L
Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
[TBL] [Abstract][Full Text] [Related]
30. Chemogenomics knowledge-based strategies in drug discovery.
Jacoby E; Schuffenhauer A; Floersheim P
Drug News Perspect; 2003 Mar; 16(2):93-102. PubMed ID: 12792670
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel BRAF kinase inhibitors with structure-based virtual screening.
Park H; Choi H; Hong S; Hong S
Bioorg Med Chem Lett; 2011 Oct; 21(19):5753-6. PubMed ID: 21873050
[TBL] [Abstract][Full Text] [Related]
32. Computational analysis of activity and selectivity cliffs.
Peltason L; Bajorath J
Methods Mol Biol; 2011; 672():119-32. PubMed ID: 20838966
[TBL] [Abstract][Full Text] [Related]
33. Proteochemometric recognition of stable kinase inhibition complexes using topological autocorrelation and support vector machines.
Fernandez M; Ahmad S; Sarai A
J Chem Inf Model; 2010 Jun; 50(6):1179-88. PubMed ID: 20524632
[TBL] [Abstract][Full Text] [Related]
34. Kinase chemogenomics: targeting the human kinome for target validation and drug discovery.
ter Haar E; Walters WP; Pazhanisamy S; Taslimi P; Pierce AC; Bemis GW; Salituro FG; Harbeson SL
Mini Rev Med Chem; 2004 Mar; 4(3):235-53. PubMed ID: 15032672
[TBL] [Abstract][Full Text] [Related]
35. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
36. High-throughput biochemical kinase selectivity assays: panel development and screening applications.
Card A; Caldwell C; Min H; Lokchander B; Hualin Xi ; Sciabola S; Kamath AV; Clugston SL; Tschantz WR; Leyu Wang ; Moshinsky DJ
J Biomol Screen; 2009 Jan; 14(1):31-42. PubMed ID: 19073965
[TBL] [Abstract][Full Text] [Related]
37. Chemical fragments as foundations for understanding target space and activity prediction.
Sutherland JJ; Higgs RE; Watson I; Vieth M
J Med Chem; 2008 May; 51(9):2689-700. PubMed ID: 18386916
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
39. A quantitative analysis of kinase inhibitor selectivity.
Karaman MW; Herrgard S; Treiber DK; Gallant P; Atteridge CE; Campbell BT; Chan KW; Ciceri P; Davis MI; Edeen PT; Faraoni R; Floyd M; Hunt JP; Lockhart DJ; Milanov ZV; Morrison MJ; Pallares G; Patel HK; Pritchard S; Wodicka LM; Zarrinkar PP
Nat Biotechnol; 2008 Jan; 26(1):127-32. PubMed ID: 18183025
[TBL] [Abstract][Full Text] [Related]
40. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
Cox KJ; Shomin CD; Ghosh I
Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
